Adaptimmune Therapeutics PLC ADAPY
$0.03
Last Updated: Aug 21, 12:00 AM·OOTC
Pricing for US stocks is delayed by 24 hours
ADAPY Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Adaptimmune Therapeutics PLC is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Adaptimmune Therapeutics PLC. Stock Analysis ADAPY
United States Health Care Nano Cap Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 506 full-time employees. The company went IPO on 2015-05-06. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). The company is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Adaptimmune Therapeutics PLC (ADAPY) Chart
Financial Metrics & Statements of Adaptimmune Therapeutics PLC (ADAPY)
FAQ's for Adaptimmune Therapeutics PLC (ADAPY)
- As of August 2026, Adaptimmune Therapeutics PLC ADAPY is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Adaptimmune Therapeutics PLC using these criteria to determine its compliance status.
- Muslim investors may consider investing in Adaptimmune Therapeutics PLC if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Adaptimmune Therapeutics PLC by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Adaptimmune Therapeutics PLC may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Adaptimmune Therapeutics PLC on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Adaptimmune Therapeutics PLC (ADAPY)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
